Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 1(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06954805Phase 2Recruiting

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Role: lead

NCT02091063Phase 1Terminated

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Role: lead

NCT01947140Phase 1Completed

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

Role: lead

NCT03355768Phase 3Withdrawn

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Role: lead

All 4 trials loaded